Synapse - Breast Medicine Service

Results (4181)

Limited absorption of low dose 10µg intravaginal 17-β Estradiol (Vagifem®) in postmenopausal women with breast cancer on aromatase inhibitors

Meeting Abstract

Goldfarb, S. B.; Dickler, M.; Dnistrian, A.; Patil, S.; Dunn, L.; Chang, K.; Berkowitz, A.; Tucker, N.; Carter, J.; Barakat, R.; more...
Cancer Research (2012)

Fulltext@MSK | Save

EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial

Meeting Abstract

Rimm, D.; Ballman, K. V.; Cheng, H.; Vassilakopoulou, M.; Chen, B.; Gralow, J.; Hudis, C.; Davidson, N. E.; Psyrri, A.; Fountzilas, G.; more...
Cancer Research (2012)

Fulltext@MSK | Save

Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

Meeting Abstract

Romond, E.; Suman, V. J.; Jeong, J. H.; Sledge, G. W. Jr; Geyer, C. E. Jr; Martino, S.; Rastogi, P.; Gralow, J.; Swain, S. M.; Winer, E.; more...
Cancer Research (2012)

Fulltext@MSK | Save

Clinical trial designs for new therapies: What endpoints should we use?

Meeting Abstract

Hudis, C. A.
Cancer Research (2012)

Fulltext@MSK | Save

Novel and targeted therapies

Book Section

Zauderer, M. G.; Traina, T. A.; Lichtman, S. M.
In Naeim, A.; Reuben, D. B.; Ganz, P. A. (Eds.) Management of Cancer in the Older Patient (2012)

Fulltext@MSK | Save

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)